SBIR-STTR Award

Oral Absorbable LMW Heparin Derivatives, In Vivo Studies
Award last edited on: 3/1/07

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$99,858
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Sigmund E Lasker

Company Information

Lambda Associates Inc

Box 13
Valhalla, NY 10595
   N/A
   N/A
   N/A
Location: Single
Congr. District: 17
County: Westchester

Phase I

Contract Number: 1R43HL061153-01A2
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2000
Phase I Amount
$99,858
This is a phase I application that proposes to develop newly orally absorbable low molecular weight heparin compounds for anticoagulant therapy for the treatment of thrombotic diseases. The specific aims will be to prepare low molecular weight heparin compounds that are orally absorbable. Preliminary studies will focus on the molecular structures that enhance absorbtion and demonstrate in vitro and in vivo antithrombotic activity. Animal studies in rats will be performed to establish absorpton from two intestinal sites. Loops of the ileus and the colon will be used in separate experiments as test absorption sites. Blood sampling from the corotid will be used to assay for antithrombotic activity.

Thesaurus Terms:
drug delivery system, drug design /synthesis /production, heparin, molecular weight, oral administration anticoagulant, gastrointestinal drug absorption laboratory rat

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----